Announced details
Mild to moderate male stress urinary incontinence caused by urinary sphincter dysfunction occurring after surgery for benign prostatic hyperplasia or prostate cancer, in patients for whom behavioral therapy and drug therapy are ineffective or insufficiently effective.
Estimated peak eligible patient population: 2,118.
The Company's subsidiary, ADRセラピューティクス株式会社, manufactures and markets this product, and the Company Group is proceeding with the insurance coverage application process.
The Medical Materials Expert Organization of the Central Social Insurance Medical Council. It is described as the organization that deliberates on the categories and prices of medical materials before formal notification and other procedures by the Ministry of Health, Labour and Welfare.
Insurance reimbursement price (preliminary indication): ¥860,000. The price was calculated using the cost-based pricing method.
The impact on consolidated results for the fiscal year ending March 2027 is currently under review, taking into account the timing of formal insurance coverage, the implementation plan for the post-marketing study, and the product supply structure.
The company does not address Contract Value.
National Cancer Center Cancer Information Service (National Cancer Registry); Medical Materials Expert Organization materials
| Item | Details |
|---|---|
| Names of Products / Services Covered | Cellution Cell Therapy Kit SUI |
| Counterparty | Medical Materials Expert Organization of the Central Social Insurance Medical Council (保材専) |
| Counterparty overview | The Medical Materials Expert Organization of the Central Social Insurance Medical Council. It is described as the organization that deliberates on the categories and prices of medical materials before formal notification and other procedures by the Ministry of Health, Labour and Welfare. |
| Relationship with the Company | The Company's subsidiary, ADRセラピューティクス株式会社, manufactures and markets this product, and the Company Group is proceeding with the insurance coverage application process. |
| Offering price | Insurance reimbursement price (preliminary indication): ¥860,000. The price was calculated using the cost-based pricing method. |
| Applicable area | Mild to moderate male stress urinary incontinence caused by urinary sphincter dysfunction occurring after surgery for benign prostatic hyperplasia or prostate cancer, in patients for whom behavioral therapy and drug therapy are ineffective or insufficiently effective. |
| Quantitative Effects | Estimated peak eligible patient population: 2,118. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review, taking into account the timing of formal insurance coverage, the implementation plan for the post-marketing study, and the product supply structure. |
| Source | National Cancer Center Cancer Information Service (National Cancer Registry); Medical Materials Expert Organization materials |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following deliberations by the Medical Materials Expert Organization of the Central Social Insurance Medical Council, the Company received preliminary notification of the insurance coverage category and reimbursement price.